Calidi Biotherapeutics (NYSE American: CLDI) was featured in a recent article that showcased the company as a compelling example of progress of emerging therapies and advances that are reshaping the fight...
Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing...
T he American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United...
Calidi Biotherapeutics (NYSE American: CLDI) announced the successful closing of a public offering of 4,437,869 shares of common stock at $1.69 per share, raising approximately $7.5 million in gross proceeds....
Calidi Biotherapeutics (NYSE American: CLDI) presented data at the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annual Meeting highlighting its RTNova systemic...
Calidi Biotherapeutics closed a public offering of approximately 4.4 million shares, raising $7.5 million for its cancer therapies.Quiver AI SummaryCalidi Biotherapeutics Inc. has successfully closed a...
Calidi Biotherapeutics (NYSE American: CLDI) has announced plans to sell shares of its common stock and/or pre-funded warrants in a public offering with Ladenburg Thalmann & Co. Inc. as the exclusive placement...